Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

At the heart of this discovery lies the role of glucagon-like peptide-1 (GLP-1), a hormone known for its involvement in ...

Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse ...

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...

When Trova Wine and Market in Dallas shut its doors last month after nearly five years in business, owner Michelle Bonds ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...

People taking weight loss medications like Ozempic may want to modify their exercise routine in order to reap the maximum benefits of these drugs while staying healthy overall. Here's how to safely ...

In response to the growing interest in glucagon-like peptide-1 (GLP-1) weight-loss medications and the cost challenges employers face to offer coverage, Liviniti, a national leader in PBM innovation, ...

A groundbreaking national poll conducted on behalf of the Diabetes Patient Advocacy Coalition (DPAC) reveals overwhelming bipartisan support for Medicare and Medicaid coverage of glucagon-like peptide ...

There used to be no specific treatments for heart failure with preserved ejection fraction, but recent clinical trials show ...

You know something is a big deal when Big Food gets nervous. The culprit? Popular weight-loss drugs like Ozempic, which mimic the hormone glucagon-like peptide-1 (GLP-1) to curb hunger. But these ...